First published · Last updated
The CALLY Index for Unresectable or Recurrent Gastric Cancer Treated With Nivolumab: A Multicenter Retrospective Study
A multicenter retrospective journal article evaluating the CALLY Index in patients with unresectable or recurrent gastric cancer treated with nivolumab.
Categories: science-and-space, public-health
Generated scores
Scores are based on the cited reporting and use a 1–10 scale. Read the methodology.
- Confidence
- 2/10
- Geographic reach
- 2/10
- Global importance
- 3/10
- Impact magnitude
- 3/10
- Positivity
- 5/10
- Urgency
- 2/10
Why it matters
The study concerns clinical assessment tools for gastric cancer patients receiving nivolumab.
Sources
- The CALLY Index for Unresectable or Recurrent Gastric Cancer Treated With Nivolumab: A Multicenter Retrospective StudyMetadata provided by Crossref. Usage terms

